CBD and CBDV have powerful antifungal activity

Fungal infections are increasingly recognized as a serious public health problem, affecting over a billion people worldwide every year. In the face of antifungal resistance and the lack of therapeutic innovation, researchers are exploring new avenues, including compounds derived from cannabis.

A recent study provides convincing evidence that cannabidiol (CBD) and the cannabidivarin (CBDV), two phytocannabinoids have significant antifungal activity, particularly against Cryptococcus neoformans, a fungus classified by the World Health Organization as a critical priority pathogen.

Promising laboratory and in vivo results

In a study evaluating five phytocannabinoids, the researchers found that CBD and the CBDV both had broad-spectrum antifungal effects. The study focused on Cryptococcus neoformans, a deadly fungus that is particularly dangerous for immunocompromised people. It is worth noting that cannabinoids acted in the same way as fungicide rather than fungistatic, meaning that they killed the fungus rather than simply inhibiting its growth.

According to the authors, « CBD and in particular CBDV have broad activity against C. neoformans and other fungal pathogens, including the dermatophytes that cause common ringworm. »These dermatophytes, responsible for conditions such as « marginal eczema »and the« athlete's foot »These are widespread in the general population and represent a major opportunity for new treatments.

The study also revealed that CBD and CBDV effectively prevented the formation of biofilms, a major virulence factor that helps fungi resist current antifungal drugs. In addition to reducing capsule size, which is another C. neoformans, cannabinoids disrupted mature biofilms and altered fungal cell morphology.

Insights from comparative proteomics

Using a proteomic analysis The research team then explored the mechanism behind this antifungal effect. They discovered that CBD and CBDV destabilized fungal cell membranes and interfered with the ergosterol biosynthesis, a key component of fungal membranes. This disruption has spread to various metabolic pathways and was linked to the function of mitochondria-associated proteins, indicating a complex but targeted mechanism of action.

«These results illustrate how phytocannabinoids could exert selective pressure on fungal physiology,» noted the researchers.

This discovery could prove particularly valuable in understanding how to design drugs that do not contribute to resistance, one of the major challenges of current antifungal treatments.

In vivo effectiveness: from lab to burns

The study went beyond the Petri dish. Using the Galleria mellonella burn pattern, the researchers tested the CBD to eliminate C. neoformans in a living organism. CBD-treated larvae showed a « significant improvement in survival »This suggests real therapeutic potential for antifungal applications. topical.

«In vivo survival of G. mellonella was significantly improved after infection with C. neoformans, underlining CBD's clear potential as an antifungal agent,» the researchers concluded.

While the CBD and the CBDV are mainly recognized for their role in neurological treatments, This research extends their field of application to infectious diseases. Thanks to their proven safety and increasing availability, these cannabinoids are well placed to be reused in clinics.

As the study points out, «the demonstrated efficacy of CBD and CBDV as broad-spectrum antifungal agents, coupled with their established safety profile, makes them a promising resource for the development of future therapeutic interventions».